{"id":1280066,"date":"2024-03-20T07:36:45","date_gmt":"2024-03-20T02:06:45","guid":{"rendered":"https:\/\/trak.in\/stories\/?p=1280066"},"modified":"2024-03-20T07:37:06","modified_gmt":"2024-03-20T02:07:06","slug":"rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now","status":"publish","type":"post","link":"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/","title":{"rendered":"Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now"},"content":{"rendered":"\n

With the aim of improving affordability to the patients, a generic version of anti-cancer drug olaparib has been introduced by Zydus Lifesciences of India. The reduced cost of the medicine reduces the overall cost of the treatment. Used in treatment of cancers ranging from breast, ovarian, prostate, and pancreatic, this generic medicine targets specific genetic mutations which is associated with these cancers, enabling tailored treatment.<\/p>\n\n\n\n

\"Rs<\/figure>\n\n\n\n

Zydus’ Affordable Olaparib & Sigh of Relief for Indian Cancer Patients<\/strong><\/p>\n\n\n\n

Majority of the 1.4 million new cancer cases in India can be treatable with this medicine. Zydus hopes to address and ease the financial burden <\/a>on the patients with this economical alternative. Historically, there has been a demand to reduce the high cost of original dose, and the invent of olaparib substantially improves the patient access to vital medication.<\/p>\n\n\n\n

The reason why the drug could be made affordable was the expiration of certain patents, hence paving the way for the invent of affordable versions. <\/p>\n\n\n\n

Patent & Their Impact on Healthcare Access<\/strong><\/p>\n\n\n\n

A generic olaparib launch was pioneered by Natco Pharma. This latest development in the pharma and medical world also brings forth the need for systematic evaluation of patent-related effects on healthcare access and underscores the patent impact on medicine accessibility.<\/p>\n\n\n\n

Emphasizing the need to address patent-related barriers by some institutional barriers, Lawyer K. Gopakumar advocates for leveraging existing legal provisions to improve medicine access.<\/p>\n\n\n\n

Speaking about the drug, then the usage of the same across stages of cancer highlights its versatility in treatment methods. This further lays importance on the fact that the drug\u2019s affordability as well as accessibility was a major roadblock for it to truly help cancer patients across financial strata.<\/p>\n","protected":false},"excerpt":{"rendered":"

With the aim of improving affordability to the patients, a generic version of anti-cancer drug olaparib has been introduced by Zydus Lifesciences of India. The reduced cost of the medicine reduces the overall cost of the treatment. Used in treatment of cancers ranging from breast, ovarian, prostate, and pancreatic, this generic medicine targets specific genetic […]<\/p>\n","protected":false},"author":26,"featured_media":1280163,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21],"tags":[4932,4933],"class_list":["post-1280066","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-cancer-drug","tag-zydus"],"acf":[],"yoast_head":"\nRs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now - Trak.in - Indian Business of Tech, Mobile & Startups<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now - Trak.in - Indian Business of Tech, Mobile & Startups\" \/>\n<meta property=\"og:description\" content=\"With the aim of improving affordability to the patients, a generic version of anti-cancer drug olaparib has been introduced by Zydus Lifesciences of India. The reduced cost of the medicine reduces the overall cost of the treatment. Used in treatment of cancers ranging from breast, ovarian, prostate, and pancreatic, this generic medicine targets specific genetic […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/\" \/>\n<meta property=\"og:site_name\" content=\"Trak.in - Indian Business of Tech, Mobile & Startups\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-20T02:06:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-20T02:07:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/03\/ify-14-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"465\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Rohit Kulkarni\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Rohit Kulkarni\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/\",\"url\":\"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/\",\"name\":\"Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now - Trak.in - Indian Business of Tech, Mobile & Startups\",\"isPartOf\":{\"@id\":\"https:\/\/trak.in\/stories\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/03\/ify-14-2.png\",\"datePublished\":\"2024-03-20T02:06:45+00:00\",\"dateModified\":\"2024-03-20T02:07:06+00:00\",\"author\":{\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/4486219a5d31e657b529e6e874cead8b\"},\"breadcrumb\":{\"@id\":\"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/#primaryimage\",\"url\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/03\/ify-14-2.png\",\"contentUrl\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/03\/ify-14-2.png\",\"width\":1000,\"height\":465},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/trak.in\/stories\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/trak.in\/stories\/#website\",\"url\":\"https:\/\/trak.in\/stories\/\",\"name\":\"Trak.in - Indian Business of Tech, Mobile & Startups\",\"description\":\"Trak.in is a popular Indian Business, Technology, Mobile & Startup blog featuring trending News, views and analytical take on Technology, Business, Finance, Telecom, Mobile, startups & Social Media Space\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/trak.in\/stories\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/4486219a5d31e657b529e6e874cead8b\",\"name\":\"Rohit Kulkarni\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/52ba60e3a61a3517cad7b5dd6bce76c6e7a4d8b337f4240839e8737c4ab8b1bb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/52ba60e3a61a3517cad7b5dd6bce76c6e7a4d8b337f4240839e8737c4ab8b1bb?s=96&d=mm&r=g\",\"caption\":\"Rohit Kulkarni\"},\"url\":\"https:\/\/trak.in\/stories\/author\/rohit-kulkarni\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now - Trak.in - Indian Business of Tech, Mobile & Startups","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/","og_locale":"en_US","og_type":"article","og_title":"Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now - Trak.in - Indian Business of Tech, Mobile & Startups","og_description":"With the aim of improving affordability to the patients, a generic version of anti-cancer drug olaparib has been introduced by Zydus Lifesciences of India. The reduced cost of the medicine reduces the overall cost of the treatment. Used in treatment of cancers ranging from breast, ovarian, prostate, and pancreatic, this generic medicine targets specific genetic […]","og_url":"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/","og_site_name":"Trak.in - Indian Business of Tech, Mobile & Startups","article_published_time":"2024-03-20T02:06:45+00:00","article_modified_time":"2024-03-20T02:07:06+00:00","og_image":[{"width":1000,"height":465,"url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/03\/ify-14-2.png","type":"image\/png"}],"author":"Rohit Kulkarni","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Rohit Kulkarni","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/","url":"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/","name":"Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now - Trak.in - Indian Business of Tech, Mobile & Startups","isPartOf":{"@id":"https:\/\/trak.in\/stories\/#website"},"primaryImageOfPage":{"@id":"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/#primaryimage"},"image":{"@id":"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/#primaryimage"},"thumbnailUrl":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/03\/ify-14-2.png","datePublished":"2024-03-20T02:06:45+00:00","dateModified":"2024-03-20T02:07:06+00:00","author":{"@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/4486219a5d31e657b529e6e874cead8b"},"breadcrumb":{"@id":"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/#primaryimage","url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/03\/ify-14-2.png","contentUrl":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/03\/ify-14-2.png","width":1000,"height":465},{"@type":"BreadcrumbList","@id":"https:\/\/trak.in\/stories\/rs-72-lakh-cancer-drug-now-available-at-rs-3-lakh-as-patent-ends-24-times-less-expensive-now\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/trak.in\/stories\/"},{"@type":"ListItem","position":2,"name":"Rs 72 Lakh Cancer Drug Now Available At Rs 3 Lakh As Patent Ends: 24-Times Less Expensive Now"}]},{"@type":"WebSite","@id":"https:\/\/trak.in\/stories\/#website","url":"https:\/\/trak.in\/stories\/","name":"Trak.in - Indian Business of Tech, Mobile & Startups","description":"Trak.in is a popular Indian Business, Technology, Mobile & Startup blog featuring trending News, views and analytical take on Technology, Business, Finance, Telecom, Mobile, startups & Social Media Space","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/trak.in\/stories\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/4486219a5d31e657b529e6e874cead8b","name":"Rohit Kulkarni","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/52ba60e3a61a3517cad7b5dd6bce76c6e7a4d8b337f4240839e8737c4ab8b1bb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/52ba60e3a61a3517cad7b5dd6bce76c6e7a4d8b337f4240839e8737c4ab8b1bb?s=96&d=mm&r=g","caption":"Rohit Kulkarni"},"url":"https:\/\/trak.in\/stories\/author\/rohit-kulkarni\/"}]}},"jetpack_featured_media_url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/03\/ify-14-2.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1280066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/comments?post=1280066"}],"version-history":[{"count":2,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1280066\/revisions"}],"predecessor-version":[{"id":1280164,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1280066\/revisions\/1280164"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/media\/1280163"}],"wp:attachment":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/media?parent=1280066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/categories?post=1280066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/tags?post=1280066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}